Androderm’s Metabolic Benefits in Hypogonadal T2DM Men: Evidence Synthesis
Reading Time: < 1 minute Introduction Testosterone deficiency, or hypogonadism, is prevalent among American males with type 2 diabetes mellitus (T2DM), affecting up to 50% of this demographic according to data from the National Health and Nutrition Examination Survey (NHANES). This endocrine disorder exacerbates insulin resistance, visceral adiposity, and dyslipidemia, compounding metabolic dysregulation. Androderm, a transdermal testosterone patch, delivers physiologic testosterone replacement therapy (TRT) via a matrix diffusion system, bypassing first-pass hepatic metabolism. This article synthesizes endocrinological evidence from recent prospective studies, elucidating Androderm's modulatory effects on metabolic health parameters in hypogonadal U.S. men aged 45-65 with T2DM. Prevalence and Pathophysiology of Hypogonadism in T2DM...


